Idvynso uniquely offers a two-drug, tenofovir-free, non-INSTI single-tablet regimen intended for switch in stable, suppressed ...
Islatravir-doravirine matched alternate regimens in two phase III trials ...
Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...
FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard ...
Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV.
During the first 2 years after switching from protease inhibitors to INSTIs, diabetes risk was higher, but not thereafter. HealthDay News — Switching to integrase strand transfer inhibitors (INSTI) ...
Switching to INSTI-based ART from protease inhibitors is associated with an increased risk for incident diabetes in treatment-experienced adults.
The researchers found that weight gain did not explain effect of switching from protease inhibitors to INSTIs on diabetes risk. HealthDay News — Switching to integrase strand transfer inhibitors ...
This approval marks an important new chapter in Merck’s long-standing commitment to research and discovery for people living ...
INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...
Merck , known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIAtm (clesrovimab) for the prevention of respiratory syncytial virus ...
Primary outcome measures The primary outcome was time to HIV care attrition, defined as death, discontinuation of ...